Released on = April 13, 2006, 8:00 am

Press Release Author = Covance Inc.

Industry = Pharmaceuticals

Press Release Summary = - Affordable, Fast Start-up Solutions Extend Automation to
Small and Non-Complex Clinical Trials and Postmarketing Studies -

Press Release Body = Princeton, NJ, April 10, 2006 - Covance Inc. (NYSE: CVD) today
announced the availability of the Covance Express SuiteSM of Interactive Voice
Response Services (IVRS) - affordable, fast start-up IVRS solutions for small,
non-complex clinical trials. The Express Suite comprises pre-configured solutions to
address the most common patient enrollment, randomization, and drug supply
management needs of biopharmaceutical firms sponsoring trials and studies where
automated methods have not previously been a viable or cost-effective option. The
Express Suite provides sponsors with a study-wide view of patient and drug supply
activity enabling them to monitor progress, anticipate problems, and take preventive
actions before they occur.
"Small and non-complex clinical studies are frequently burdened with error-prone
manual processes, and unfortunately electronic data capture - with hand-held devices
or even traditional interactive voice response technology - has been seen as too
expensive, too complex and difficult to get off the ground," said Jim Denmark,
General Manager of Covance IVRS. "With the Express Suite, Covance is delivering the
best of all worlds - a fast start-up, affordable, off-the-shelf solution, with the
benefit of automated data capture, analysis, and reporting, all backed by Covance's
extensive clinical expertise."

From a patient enrollment and drug supply management perspective, clinical trials
and postmarketing studies may be characterized by the number of investigator sites,
geographic reach, and duration. The Express Suite provides an ideal solution for
trials or studies with less than fifty investigator sites, up to five drug supply
depots/geographies, and an expected duration of up to two years.

The Express Suite leverages Covance's proven interactive voice response technology.
Express Suite solutions for patient enrollment, randomization and drug supply
management can be assembled quickly from production proven, reusable modules.
Because custom programming is not required, the implementation process is much
faster than for custom-built systems, and sponsors can soon begin realizing the
benefits of an automated solution.

About Covance Interactive Voice Response Services
Covance Interactive Voice Response Services, a unit of the Covance Late Stage
Development Services business, helps biopharmaceuctical clients automate key study
activities and manage drug supply for their clinical trials and postmarketing
studies. Beginning in 1989, Covance was the first company to apply interactive
voice response technology to pharmaceutical clinical research, and has successfully
implemented hundreds of patient enrollment, drug supply management and patient diary
solutions in dozens of languages involving thousands of patients in countries around
the world. Covance IVRS solutions range from highly complex, customized study
designs to the Express Suite of affordable, fast start-up solutions for small and
non-complex clinical trials.

About Covance
Covance, with headquarters in Princeton, New Jersey, is one of the world\'s largest
and most comprehensive drug development services companies with annual revenues
greater than $1 billion, global operations in more than 20 countries, and more than
7,300 employees worldwide. Information on Covance's products and services, recent
press releases, and SEC filings can be obtained through its website at
www.covance.com.

Statements contained in this press release, which are not historical facts, are
forward-looking statements pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. All such forward-looking statements
including the statements contained herein regarding anticipated trends in the
Company's business are based largely on management's expectations and are subject to
an qualified by risks and uncertainties that could cause actual results to differ
materially from those expressed or implied by such statements. These risks and
uncertainties include, without limitation, competitive factors, outsourcing trends
in the pharmaceutical industry, levels of industry research and development
spending, the Company's ability to continue to attract and retain qualified
personnel, the fixed price nature of contracts or the loss of large contracts, and
other factors described in the Company's filings with the Securities and Exchange
Commission.

Covance and the Covance logo are registered service marks and "Express Suite" is a
service mark of Covance in the United States and other countries.


Web Site = http://www.covance.com/news/pressrel/2006/060410.php

Contact Details = 210 Carnegie Center
Princeton, NJ 08540

609 452 4159
pr@covance.com